196 related articles for article (PubMed ID: 33789001)
1. The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders.
Lee SK; Gupta M; Shi J; McKeever K
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1325-1334. PubMed ID: 33789001
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With Triheptanoin.
Lee SK; Gosselin NH; Jomphe C; McKeever K; Putnam W
Clin Pharmacol Drug Dev; 2022 Nov; 11(11):1264-1272. PubMed ID: 35908210
[TBL] [Abstract][Full Text] [Related]
3. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
[TBL] [Abstract][Full Text] [Related]
4. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Gillingham MB; Heitner SB; Martin J; Rose S; Goldstein A; El-Gharbawy AH; Deward S; Lasarev MR; Pollaro J; DeLany JP; Burchill LJ; Goodpaster B; Shoemaker J; Matern D; Harding CO; Vockley J
J Inherit Metab Dis; 2017 Nov; 40(6):831-843. PubMed ID: 28871440
[TBL] [Abstract][Full Text] [Related]
5. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
Vockley J; Burton B; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman K; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Cataldo J
J Inherit Metab Dis; 2021 Jan; 44(1):253-263. PubMed ID: 32885845
[TBL] [Abstract][Full Text] [Related]
6. Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.
Vockley J; Burton BK; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman KA; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Rahman S; Ray K; Reineking B; Pisani L; Ramirez AN
J Inherit Metab Dis; 2023 Sep; 46(5):943-955. PubMed ID: 37276053
[TBL] [Abstract][Full Text] [Related]
7. Long-chain fatty acid oxidation disorders and current management strategies.
Vockley J
Am J Manag Care; 2020 Aug; 26(7 Suppl):S147-S154. PubMed ID: 32840329
[TBL] [Abstract][Full Text] [Related]
8. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
Vockley J; Charrow J; Ganesh J; Eswara M; Diaz GA; McCracken E; Conway R; Enns GM; Starr J; Wang R; Abdenur JE; Sanchez-de-Toledo J; Marsden DL
Mol Genet Metab; 2016 Nov; 119(3):223-231. PubMed ID: 27590926
[TBL] [Abstract][Full Text] [Related]
9. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
[TBL] [Abstract][Full Text] [Related]
10. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
[TBL] [Abstract][Full Text] [Related]
11. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Humphrey R; Mayhew J; Bowden A; Zhang L; Cataldo J; Marsden DL; Kakkis E
Mol Genet Metab; 2017 Apr; 120(4):370-377. PubMed ID: 28189603
[TBL] [Abstract][Full Text] [Related]
12. Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study.
Vockley J; Longo N; Madden M; Dwyer L; Mu Y; Chen CY; Cataldo J
Clin Nutr ESPEN; 2021 Feb; 41():293-298. PubMed ID: 33487279
[TBL] [Abstract][Full Text] [Related]
13. Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats.
Kinman RP; Kasumov T; Jobbins KA; Thomas KR; Adams JE; Brunengraber LN; Kutz G; Brewer WU; Roe CR; Brunengraber H
Am J Physiol Endocrinol Metab; 2006 Oct; 291(4):E860-6. PubMed ID: 16705058
[TBL] [Abstract][Full Text] [Related]
14. Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program.
Yang E; Kruger E; Yin D; Mace K; Tierney M; Liao N; Cibelli E; Drozd D; Ross N; Deering KL; Herout P; Harshaw Q; Shillington A; Thomas N; Marsden D; Kritzer A; Vockley J
Mol Genet Metab; 2024 May; 142(1):108350. PubMed ID: 38458123
[TBL] [Abstract][Full Text] [Related]
15. Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders.
Sklirou E; Alodaib AN; Dobrowolski SF; Mohsen AA; Vockley J
Front Genet; 2020; 11():598760. PubMed ID: 33584796
[TBL] [Abstract][Full Text] [Related]
16. Heptanoate Improves Compensatory Mechanism of Glucose Homeostasis in Mitochondrial Long-Chain Fatty Acid Oxidation Defect.
Nurjanah S; Gerding A; Vieira-Lara MA; Evers B; Langelaar-Makkinje M; Spiekerkoetter U; Bakker BM; Tucci S
Nutrients; 2023 Nov; 15(21):. PubMed ID: 37960342
[TBL] [Abstract][Full Text] [Related]
17. Higher dietary protein intake preserves lean body mass, lowers liver lipid deposition, and maintains metabolic control in participants with long-chain fatty acid oxidation disorders.
Gillingham MB; Elizondo G; Behrend A; Matern D; Schoeller DA; Harding CO; Purnell JQ
J Inherit Metab Dis; 2019 Sep; 42(5):857-869. PubMed ID: 31295363
[TBL] [Abstract][Full Text] [Related]
18. Management and diagnosis of mitochondrial fatty acid oxidation disorders: focus on very-long-chain acyl-CoA dehydrogenase deficiency.
Yamada K; Taketani T
J Hum Genet; 2019 Feb; 64(2):73-85. PubMed ID: 30401918
[TBL] [Abstract][Full Text] [Related]
19. Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program.
Vockley J; Enns GM; Ramirez AN; Bedrosian CL; Reineking B; Lu X; Ray K; Rahman S; Marsden D
Mol Genet Metab; 2022 Jun; 136(2):152-162. PubMed ID: 35459555
[TBL] [Abstract][Full Text] [Related]
20. Long-term experience with triheptanoin in 12 Austrian patients with long-chain fatty acid oxidation disorders.
Zöggeler T; Stock K; Jörg-Streller M; Spenger J; Konstantopoulou V; Hufgard-Leitner M; Scholl-Bürgi S; Karall D
Orphanet J Rare Dis; 2021 Jan; 16(1):28. PubMed ID: 33446227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
